Longeveron (LGVN) Price & Analysis

Compare

621 Followers

LGVN Stock Chart & Stats

$0.96

-$0.07(-3.68%)

At close: Jan 08 4:00 PM EST

$0.96

-$0.07(-3.68%)

Day’s Range― - ―

52-Week Range$0.48 - $1.92

Previous CloseN/A

Volume215.49K

Average Volume (3M)473.11K

Market Cap

$20.48M

Enterprise Value$16.64M

Total Cash (Recent Filing)$9.24M

Total Debt (Recent Filing)$983.00K

Price to Earnings (P/E)―

Beta1.52

Next Earnings

May 08, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding19,848,877

10 Day Avg. Volume706,553

30 Day Avg. Volume473,105

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.57

Price to Sales (P/S)7.42

P/FCF Ratio-0.48

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue11.58

Enterprise Value/Gross Profit15.47

Enterprise Value/Ebitda-0.81

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)-0.84

Revenue Forecast (FY)$715.67K

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressSurvival data has been encouraging from ELPIS I long-term follow-ups, with 100% survival at 5 years of age compared to a 20% mortality at 5 years for historical control.

Financial SupportGrant funding from the National Institute of Health helps offset study expenses, enhancing the company's financial position.

Regulatory EnvironmentThe first approved mesenchymal cell therapy continues to gain traction in another pediatric rare disease at premium pricing and an overall more favorable regulatory environment for cell-based therapies.

Bears Say

Equity FinancingThe company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.

Longeveron News

Longeveron price target lowered to $2 from $3 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $2 from $3 but keeps a Buy...

6h ago

LGVN

3 Penny Stocks to Watch Now, 3/11/26

Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3 Penny Stocks to watch on March 11, based...

8d ago

ATPC

INKT

Longeveron prices 6.01M shares at 52c in private placement

Longeveron (LGVN) entered into a definitive agreement with certain institutional and accredited investors for up to approximately $30M...

9d ago

LGVN

Longeveron: Phase 2b results show laromestrocel improved physical condition

Longeveron (LGVN) announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell,...

22d ago

LGVN

Longeveron Earnings Call: Pivotal Trials, Tight Cash

Longeveron Inc. (($LGVN)) has held its Q4 earnings call. Read on for the main highlights of the call....

6h ago

LGVN

Longeveron Announces $30 Million Private Placement Financing

Longeveron ( ($LGVN) ) has issued an update. On March 10, 2026, Longeveron entered into a securities purchase...

6d ago

LGVN

LGVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Longeveron Inc. (LGVN) is scheduled to report 4th quarter earnings on 03/06/2026. Regarding Q4 estimates, Wall Street analysts...

15d ago

LGVN

Longeveron Appoints New CEO Amid Cost-Cutting Initiatives

Longeveron ( ($LGVN) ) has provided an update. On February 9, 2026, interim CEO Than Powell resigned from...

1M ago

LGVN

Longeveron names Stephen Willard as CEO, succeeding Than Powell

Longeveron (LGVN) announced that the company’s Board of Directors has appointed Stephen Willard as CEO, effective February 11....

1M ago

LGVN

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

Longeveron (LGVN) supports and applauds Congress passing the Mikaela Naylon Give Kids a Chance Act. The Mikaela Naylon...

1M ago

LGVN

Longeveron granted Japan patent for potency assay methods for MSCs

Longeveron (LGVN) announced that the Japan Patent Office, JPO, has granted a patent covering potency assay methods for...

2M ago

LGVN

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

Longeveron (LGVN) announced that the U.S. Food and Drug Administration has granted Longeveron a Type C meeting at...

2M ago

LGVN

Longeveron granted U.S. patent for method of treating female sexual dysfunction

Longeveron (LGVN) announced that the United States Patent and Trademark Office has granted a patent covering administration of...

3M ago

LGVN

Longeveron granted Canadian patent covering laromestrocel administration

Longeveron (LGVN) announced that the Canadian Intellectual Property Office has granted a patent covering administration of laromestrocel, the...

4M ago

LGVN

LGVN FAQ

What was Longeveron’s price range in the past 12 months?

Longeveron lowest stock price was $0.47 and its highest was $1.92 in the past 12 months.

What is Longeveron’s market cap?

Longeveron’s market cap is $20.48M.

When is Longeveron’s upcoming earnings report date?

Longeveron’s upcoming earnings report date is May 08, 2026 which is in 50 days.

How were Longeveron’s earnings last quarter?

Longeveron released its earnings results on Mar 17, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.137.

Is Longeveron overvalued?

According to Wall Street analysts Longeveron’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Longeveron pay dividends?

Longeveron does not currently pay dividends.

What is Longeveron’s EPS estimate?

Longeveron’s EPS estimate is -0.23.

How many shares outstanding does Longeveron have?

Longeveron has 19,848,877 shares outstanding.

What happened to Longeveron’s price movement after its last earnings report?

Longeveron reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Longeveron?

Currently, no hedge funds are holding shares in LGVN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron (LGVN) Earnings & Revenues

Historic Earnings Reports

LGVN Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call balanced meaningful clinical and strategic progress (pivotal HLHS readout expected in Q3 2026, IND effectiveness for PDCM, publications/patents, and a $15.9M financing improving runway) against material near-term financial and operational challenges (50% revenue decline, 41% larger net loss, rising R&D/G&A spend, low year-end cash of $4.7M and reliance on additional financing or PRV monetization). While the company has clear catalysts and credible scientific validation, its liquidity profile and widened losses temper the outlook in the near term.View all LGVN earnings summaries